GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.

GH Research PLC

GH Research plc (NASDAQ: GHRS) is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.

Acuta Capital Partners

Cormorant Asset Management

RA Capital Management

RTW Investments

Logos Capital

Biotechnology Value Fund

Boxer Capital

BVF Partners

Surveyor Capital

Venrock Healthcare Capital Partners

Verition Fund Management

GH Research plc

GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates

GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights

GH Research Provides Business Updates and Highlights Key Upcoming Milestones

https://lnkd.in/eEJUSZpQ

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-310K -	-1.15M 270.65%	-9.20M 700.87%	-22.46M 144.03%	-35.59M 58.47%
depreciation and amortization		1K -	19K 1,800%	47K 147.37%	315K 570.21%
deferred income tax			-5.92M -		6.25M -
stock based compensation			366K -	1.67M 356.56%	2.29M 37.10%
change in working capital	21K -	61K 190.48%	-559K 1,016.39%	2.16M 486.23%	1.65M 23.81%
accounts receivables
inventory
accounts payables
other working capital
other non cash items			9K -	-7.62M 84,766.67%	-8.26M 8.33%
net cash provided by operating activities	-289K -	-1.09M 276.12%	-15.28M 1,305.98%	-26.20M 71.43%	-33.34M 27.24%
investments in property plant and equipment		-21K -	-104K 395.24%	-67K 35.58%	-100K 49.25%
acquisitions net
purchases of investments				-84.62M -	-54M 36.19%
sales maturities of investments
other investing activites
net cash used for investing activites		-21K -	-104K 395.24%	-84.69M 81,330.77%	-54.10M 36.12%
debt repayment					-219K -
common stock issued	797K -	5.50M 590.09%	309.20M 5,521.82%		15K -
common stock repurchased
dividends paid
other financing activites	797 -	5.50K 590.09%	-22.75M 413,790.91%
net cash used provided by financing activities	797K -	5.50M 590.09%	286.45M 5,108.13%		-204K -
effect of forex changes on cash	-10K -	-211K 2,010.00%	-179K 15.17%	66K 136.87%	105K 59.09%
net change in cash	498K -	-1.32M 364.86%	270.88M 20,636.85%	-110.82M 140.91%	-87.53M 21.01%
cash at beginning of period		5.89M -	5.89M 0%	276.78M 4,595.10%	165.96M 40.04%
cash at end of period	498K -	4.58M 818.88%	276.78M 5,948.43%	165.96M 40.04%	78.42M 52.75%
operating cash flow	-289K -	-1.09M 276.12%	-15.28M 1,305.98%	-26.20M 71.43%	-33.34M 27.24%
capital expenditure		-21K -	-104K 395.24%	-67K 35.58%	-100K 49.25%
free cash flow	-289K -	-1.11M 283.39%	-15.39M 1,288.72%	-26.27M 70.70%	-33.44M 27.30%

COM:GHRES

GH Research PLC

Last Close

9.62

22/11 21:00

Market Cap

591.56M

Beta: -

Volume Today

61.64K

Avg: -

Preview